Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 t
4 hours ago
- #immunotherapy combination
- #hepatocellular carcinoma
- #phase 2 trial
- The PRODIGE 81-FFCD 2101-TRIPLET HCC trial investigated adding ipilimumab to atezolizumab plus bevacizumab in untreated, unresectable hepatocellular carcinoma.
- Phase 2 results showed no significant benefit: 30% objective response with the triple therapy vs 27% with atezolizumab plus bevacizumab alone at 24 weeks.
- The trial did not meet the pre-specified threshold for progression to phase 3 and was stopped.
- Serious adverse events were more common with the triple combination (49% vs 42%), including 5% treatment-related deaths in the triple therapy group.
- The findings do not support adding low-dose ipilimumab to atezolizumab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma.